[Investigation of clinical effect of flomoxef].
Flomoxef (FMOX, 6315-S) is a new antibiotic of oxacephem group with a broad antibacterial spectrum. Seven patients were treated by intravenous instillation of 1 g of FMOX twice daily. Seven-day treatment with FMOX was ineffective against chronic bronchitis caused by Escherichia coli in a patient who had received an operation for esophageal cancer 6 years previously. Seven-day treatment with FMOX was effective against acute pneumonia caused by Staphylococcus aureus in a patient with lung cancer. Nine-day treatment with FMOX was effective against pulmonary suppuration caused by Streptococcus pneumoniae in a patient with lung cancer. Six-day and 7-day treatment with FMOX were excellently or moderately effective against suspected obstructive pneumonia in 2 patients with lung cancer. Five-day and 6-day treatment with FMOX were ineffective against fever of unknown origins in 2 patients with lung cancer. Overall, FMOX was effective in 4 of the 7 patients evaluated.
Pulmonary Medicine Clinic, Saitama Cancer Center Hospital.
Y
Y
Noguchi
S
S
Yoneda
Y
Y
Fukuda
M
M
Nakata
T
T
Honma
K
K
Yoshida
D000368:Aged; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology
D002511:Cephalosporins; C045693:flomoxef